Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDION study: Desmopressin OD Tablets for Early Improvement of Nocturia
jRCTs021230045Not yet recruiting
- Sponsor
- Ferring Pharmaceuticals
- Start
- Dec 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of desmopressin in nocturia and nocturnal polyuria (NP), sponsored by Ferring Pharmaceuticals. Primary endpoint: Primary endpoint: nocturnal voiding frequency at Day 28. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
desmopressin
03
Conditions
nocturianocturnal polyuria (NP)
Beyond the preview
Go deeper on jRCTs021230045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021230045.